Home > Resources > Whitepapers > Technology to the Rapid Generation of Genetically Engineered Mice

Technology to the Rapid Generation of Genetically Engineered Mice

March 27, 2014

CRISPR/Cas-based gene editing has recently emerged as a versatile technology for inducing precise genetic alterations in a number of different species, including mice and rats.Given the importance of genetically engineered mice in modeling human disease, the power of CRISPR has the potential to revolutionize the field of custom rodent model generation and facilitate biomedical research.

Spotlight

LakePharma, Inc.

LakePharma is a leading biologics company specializing in antibody and protein engineering, cell line development, and protein production. Services can be fully integrated, creating a "soup to nuts" solution for all of a customer's molecular biology, cell line, and protein needs.With facilities located in the heart of the San Francisco Bay Area and near the Boston/Cambridge biotech hub, LakePharma has developed numerous in-house technology platforms to provide cost-effective and high quality services to our customers.

OTHER WHITEPAPERS

rFC adoption for bacterial endotoxin testing

whitePaper | December 7, 2022

OVER THE LAST 20 years, the worldwide value of traded pharmaceutical goods has grown six‑fold, from $113 billion in 2000 to $629 billion in 2019.1 Yet amid such robust growth comes risk to supply chain security as manufacturers become increasingly dependent on a global network of suppliers

Advanced Biopharmaceutical Manufacturing: An Evolution Underway

whitePaper | June 5, 2022

The past decade has seen a significant shift in the nature of the products being manufactured and sold by the innovative biopharmaceutical (biopharma) industry. The global biopharmaceutical portfolio of today reflects increased therapeutic competition, a greater prevalence of large molecule drugs, expansion in the number of personalized or targeted products, and a rise of treatments for many orphan diseases.

A REVIEW OF THE RESEARCH TRENDS AND DEVELOPMENTS

whitePaper | May 9, 2022

In the last decade, there has been an encouraging shift in research, clinical development, and commercial activity to exploit the many biological roles of ribonucleic acid (RNA) for use in medicine.

State of the Global Biotech Landscape: Where the Opportunities Lie

whitePaper | December 13, 2022

Over the last five years, the global biotech and pharmaceutical landscape has witnessed continued growth. The analysis period (2017-2022) encompasses a unique timeframe including the global COVID-19 pandemic.

Asia Pacific Leads The Way In Cell & Gene Therapy Trials

whitePaper | December 16, 2022

Cell and gene therapies (CGTs) are continuing to gain momentum in life sciences globally. However, Asia Pacific (APAC) has demonstrated the most growth in CGT developers of any other region, with a rise of 10% in H1 2022 compared to 2021.1

Benefit-Risk Considerations for Product Quality Assessments; Guidance for Industry; DRAFT GUIDANCE

whitePaper | May 10, 2022

This guidance describes the benefit-risk principles applied by FDA when conducting product quality-related assessments of chemistry, manufacturing, and controls (CMC)2 19 information 20 submitted for FDA assessment as part of original new drug applications (NDAs) under section

Spotlight

LakePharma, Inc.

Events

8th International Conference on Bio-Sensing Technology

Conference

8th International Conference on Bio-Sensing Technology

Conference